APGE - Latest News
Apogee Therapeutics, Inc. (APGE), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $5.19B. Beta to the broader market is 0.69.
The article list below shows the most recent APGE headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent APGE Headlines
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
globenewswire.com - May 11, 2026
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year High – Still a Buy?
defenseworld.net - Apr 15, 2026
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report)'s share price hit a new 52-week high on Wednesday.
Apogee Therapeutics (NASDAQ:APGE) CEO Sells $1,651,600.00 in Stock
defenseworld.net - Apr 13, 2026
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction that o
Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE
defenseworld.net - Apr 10, 2026
Aberdeen Group plc lessened its stake in Apogee Therapeutics Inc. (NASDAQ: APGE) by 34.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
globenewswire.com - Mar 26, 2026
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advanci
How News Affects APGE Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track APGE's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked APGE news questions
- What is the latest APGE news headline?
- The most recent APGE headline (May 11, 2026) is "Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the APGE news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What APGE news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual APGE options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.